Chemoembolization of hepatocellular carcinoma with HepaSphere

This review discusses the current data on Hepasphere™ in the treatment of hepatocellular carcinoma. HepaSphere is a drug-loadable microsphere that can be bound with doxorubicin, epirubicin, cisplatin or oxaliplatin. and studies confirm lower systemic exposure to the drug and fewer systemic doxorubic...

Full description

Saved in:
Bibliographic Details
Published in:Hepatic oncology 2015-04, Vol.2 (2), p.147-157
Main Authors: Malagari, Katerina, Pomoni, Anastasia, Filippiadis, Dimitrios, Kelekis, Dimitrios
Format: Article
Language:English
Subjects:
conventional chemoembolization
Drug Evaluation
drug-eluting chemoembolization
hepatocellular carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review discusses the current data on Hepasphere™ in the treatment of hepatocellular carcinoma. HepaSphere is a drug-loadable microsphere that can be bound with doxorubicin, epirubicin, cisplatin or oxaliplatin. and studies confirm lower systemic exposure to the drug and fewer systemic doxorubicin-related side effects. Studies suggest that this technique is better tolerated than conventional lipiodol-based chemoembolization (c-TACE). In intermediate and early stage hepatocellular carcinoma - nonresponsive to curative treatments - complete response and partial response rates range from 22.2 to 48% and 43.7 to 51%, respectively. Studies with survival as an end-point are needed and head-to-head comparisons with other drug-eluting beads are necessary.
ISSN:2045-0923
2045-0931
DOI:10.2217/hep.15.2